Cumberland Pharmaceuticals Inc.
NASDAQ:CPIX · NASDAQ Global Select
-$0.06 today
Vol 0.03M · Avg 0.97M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-11.4%
avg -11.3%
ROIC
-6.9%
avg -8.6%
ROA
-3.7%
avg -4.7%
Analysis
ROA is currently the strongest return metric at -3.7% versus its period average of -4.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
A. J. Kazimi | Founder, Chairman, President & Chief Executive Officer | $979,849.00 | — | 68 | $568,000.00 | 3.79% |
Todd Anthony | Vice President of Organizational Development | $330,095.00 | — | 65 | $21,000.00 | 0.14% |
ChristopherT. Bitterman | Vice President of Sales & Marketing | $313,616.00 | — | 61 | $19,000.00 | 0.13% |
John Michael Hamm | Vice President Accounting & Finance and CFO | $288,224.00 | — | 70 | $18,250.00 | 0.12% |
Jean W. Marstiller | Senior Vice President of Administrative Services & Corporate Secretary | $282,168.00 | — | 76 | — | — |
James Lowrance Herman | Vice President of Trade & Distribution and Chief Compliance Officer | $211,810.00 | — | 71 | $46,863.00 | 0.31% |
Adam S. Mostafa | Managing Director of Banking & Investor Relations | — | — | 46 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -48.9% | N/A1 analysts |
| Revenue | N/A | N/A | -11.8% | +1.8% (16yr)1 analysts |
| Net Income | N/A | N/A | -50.0% | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -11.8% over three years. Forward estimates point to Revenue at +1.8% (16yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Lantern Pharma Inc.
NASDAQ:LTRN
$47.34M
LAVA Therapeutics N.V.
LVTX
$45.77M
Dyadic International, Inc.
DYAI
$29.28M
Rockwell Medical, Inc.
RMTI
$25.90M
ABVC BioPharma, Inc.
ABVC
$19.28M
Celularity Inc.
CELU
$18.08M
Quantum BioPharma Ltd.
QNTM
$16.90M
CalciMedica, Inc.
CALC
$11.93M
Inotiv, Inc.
NOTV
$2.79M
Reviva Pharmaceuticals Holdings, Inc.
RVPH
$2.05M
Who manages CPIX?
Cumberland Pharmaceuticals Inc. (CPIX) lists 7 active executives. The top listed executive is Adam S. Mostafa, Managing Director of Banking & Investor Relations.
Are CPIX insiders buying or selling?
Recent insider activity shows net buying of $346,106.63.
Explore More
Continue the stock analysis
Jump to another research area for this company.